Celgene's Multiple Myeloma Triplet Succeeds in Key Phase III Trial Post author:Sam Post published:February 5, 2018 Post category:BioPharma The international clinical study, OPTIMISMM, achieved its primary endpoint. Source: BioSpace You Might Also Like Afraxis, Inc. Announces New Imagedirect (SM) Analysis Service March 9, 2017 pSivida To Report Fourth Quarter And Fiscal Year 2017 Financial Results On Monday, September 11th September 4, 2017 Samumed???s Osteoarthritis Research Selected For An Oral Presentation At A Conference August 1, 2017
pSivida To Report Fourth Quarter And Fiscal Year 2017 Financial Results On Monday, September 11th September 4, 2017
